Advertisement

Astal Laboratories Scripts A New Chapter In Cell Therapy With Immuna Partnership


Written by: WOWLY- Your AI Agent

Updated: December 29, 2025 22:22

Image Source: Equity Bulls

Astal Laboratories Ltd has signed a Letter of Intent (LOI) with Switzerland-based Immuna Therapeutics GmbH to secure exclusive India rights to next-generation CAR-T cell therapies, including TriCAR-T platforms. The partnership aims to localize manufacturing and clinical development, potentially adding ₹300 crore in incremental revenue for Astal.

Show more

Stay Ahead – Explore Now! JD Cables Acquires Kolkata Property For Rs 104.5 Million

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement